Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Stellular Bio, Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are handled by 2 distinct examiners, yet they are both situated within 1 distinct art unit. This concentration in 1 art unit indicates that while the technical subject matter is consistent, the applicant must navigate the differing perspectives of 2 separate examiners within that specific regulatory environment. Such a structure allows the applicant to test different arguments against the same art unit standards.
The busiest examiner for this portfolio is SPENCE, JENNIFER SUZANNE, who is responsible for 1 pending office action. Given that the total pending workload consists of 2 actions, the responsibility is distributed between the identified busiest examiner and one other official. This distribution across 2 distinct examiners within 1 distinct art unit may lead to varied prosecution outcomes despite the shared technical focus of the Biotechnology & Pharmaceuticals filings. Practitioners should compare the 1 pending action under SPENCE, JENNIFER SUZANNE with the other active matter to identify any inconsistencies in examiner requirements within the same unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17985365 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | REGLAS, GILLIAN CHELSEA | 44d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17985365 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | REGLAS, GILLIAN CHELSEA | 44d overdue |
| 18787160 | Compositions and Methods for Producing Megakaryocytes | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18787160 | Compositions and Methods for Producing Megakaryocytes | SPENCE, JENNIFER SUZANNE | — | §102§103DP | Non-Final OA | — | Pending | Jul 29, 2024 |
| 17985365 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | REGLAS, GILLIAN CHELSEA | 1632 | §102§112 | Final Rejection | 44d overdue | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial